Abcellera Stock Analysis

ABCL
 Stock
  

USD 9.20  0.49  5.06%   

The small pull down in market price for the last few months could raise concerns from stakeholders as the firm is trading at a share price of 9.20 on 1,792,300 in volume. The company directors and management did not add much value to Abcellera Biologics investors in August. However, diversifying your holdings with Abcellera Biologics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.21. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Abcellera Biologics partners.
Please continue to Trending Equities.
  
The Abcellera Biologics stock analysis report makes it easy to digest most publicly released information about Abcellera Biologics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Abcellera Stock analysis module also helps to analyze the Abcellera Biologics price relationship with some important fundamental indicators such as market cap and management efficiency.

Abcellera Stock Analysis Notes

About 29.0% of the company shares are held by company insiders. The book value of Abcellera Biologics was presently reported as 3.39. The company has Price/Earnings To Growth (PEG) ratio of 2.24. Abcellera Biologics had not issued any dividends in recent years. AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. For more info on Abcellera Biologics please contact the company at 604 559 9905 or go to https://www.abcellera.com.

Abcellera Biologics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Abcellera Biologics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Abcellera Biologics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Abcellera Biologics generated a negative expected return over the last 90 days
Abcellera Biologics has high historical volatility and very poor performance
About 29.0% of the company shares are held by company insiders
Latest headline from simplywall.st: In the wake of AbCellera Biologics Inc.s latest US120m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Abcellera Biologics Upcoming and Recent Events

Earnings reports are used by Abcellera Biologics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abcellera Biologics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of April 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End4th of April 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Abcellera Biologics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Abcellera Biologics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Abcellera Biologics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Abcellera Biologics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
18th of July 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
6th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
30th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
21st of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
24th of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
15th of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View

Abcellera Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Abcellera Biologics' institutional investor refers to the entity that pools money to purchase Abcellera Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Baillie Gifford CoCommon Shares13.4 M142.2 M
Capital World InvestorsCommon Shares13 M138.9 M
Blackrock IncCommon Shares11.8 M125.9 M
Allianz Asset Management GmbhCommon Shares10.8 M115.3 M
Baker Bros Advisors LpCommon Shares10.5 M111.3 M
Orbimed Advisors LlcCommon Shares4.2 M44.5 M
Guardian Capital Advisors LpCommon Shares3.8 M44.4 M
Susquehanna International Group LlpCall Options2.2 M22.9 M
Note, although Abcellera Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Abcellera Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.59 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abcellera Biologics's market, we take the total number of its shares issued and multiply it by Abcellera Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Abcellera Profitablity

Abcellera Biologics' profitability indicators refer to fundamental financial ratios that showcase Abcellera Biologics' ability to generate income relative to its revenue or operating costs. If, let's say, Abcellera Biologics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Abcellera Biologics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Abcellera Biologics' profitability requires more research than a typical breakdown of Abcellera Biologics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 41.88 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 55.47 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.55.

Management Efficiency

The entity has return on total asset (ROA) of 12.46 % which means that it generated profit of $12.46 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 18.92 %, meaning that it created $18.92 on every $100 dollars invested by stockholders. Abcellera Biologics management efficiency ratios could be used to measure how well abcellera biologics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 25th of September, Abcellera Biologics shows the risk adjusted performance of (0.015869), and Mean Deviation of 2.93. Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Abcellera Biologics, which can be compared to its rivals. Please confirm Abcellera Biologics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 9.2 per share. Given that Abcellera Biologics has jensen alpha of (0.030253), we suggest you to validate Abcellera Biologics's prevailing market performance to make sure the company can sustain itself at a future point.

Abcellera Biologics Price Movement Analysis

The output start index for this execution was nine with a total number of output elements of fifty-two. The Moving Average is predictive technique used to analyze Abcellera Biologics price data points by creating a series of averages of different subsets of Abcellera Biologics entire price series.
.

Abcellera Biologics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Thermopylae Holdings Ltd over a month ago via Macroaxis 
Purchase by Thermopylae Holdings Ltd of 200000 shares of Abcellera Biologics
Thermopylae Holdings Ltd over three months ago via Macroaxis 
Purchase by Thermopylae Holdings Ltd of 9173 shares of Abcellera Biologics
Montalbano John S over three months ago via Macroaxis 
Acquisition by Montalbano John S of 45532 shares of Abcellera Biologics subject to Rule 16b-3
Hansen Carl L G over three months ago via Macroaxis 
Exercise or conversion by Hansen Carl L G of 56125 shares of Abcellera Biologics subject to Rule 16b-3
Thermopylae Holdings Ltd over three months ago via Macroaxis 
Purchase by Thermopylae Holdings Ltd of 300000 shares of Abcellera Biologics
Thermopylae Holdings Ltd over three months ago via Macroaxis 
Purchase by Thermopylae Holdings Ltd of 1408468 shares of Abcellera Biologics
Montalbano John S over six months ago via Macroaxis 
Abcellera Biologics exotic insider transaction detected
Montalbano John S over six months ago via Macroaxis 
Abcellera Biologics exotic insider transaction detected
Lecault Veronique over six months ago via Macroaxis 
Abcellera Biologics exotic insider transaction detected
Thermopylae Holdings Ltd over six months ago via Macroaxis 
Bona fide gift to Thermopylae Holdings Ltd of 750000 shares of Abcellera Biologics subject to Section 16
Montalbano John S over six months ago via Macroaxis 
Acquisition by Montalbano John S of 45532 shares of Abcellera Biologics subject to Rule 16b-3
Stimart Tryn over six months ago via Macroaxis 
Acquisition by Stimart Tryn of 270680 shares of Abcellera Biologics subject to Rule 16b-3

Abcellera Biologics Predictive Daily Indicators

Abcellera Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abcellera Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Abcellera Biologics Forecast Models

Abcellera Biologics time-series forecasting models is one of many Abcellera Biologics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abcellera Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Abcellera Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Abcellera Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Abcellera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Abcellera Biologics. By using and applying Abcellera Stock analysis, traders can create a robust methodology for identifying Abcellera entry and exit points for their positions.
AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States.

Current Abcellera Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Abcellera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Abcellera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Strong Buy5Odds
Abcellera Biologics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Abcellera analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Abcellera stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Abcellera Biologics, talking to its executives and customers, or listening to Abcellera conference calls.
Abcellera Analyst Advice Details

Abcellera Stock Analysis Indicators

Abcellera Biologics stock analysis indicators help investors evaluate how Abcellera Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Abcellera Biologics shares will generate the highest return on investment. By understating and applying Abcellera Biologics stock analysis, traders can identify Abcellera Biologics position entry and exit signals to maximize returns.
Quick Ratio5.25
Fifty Two Week Low5.42
Revenue Growth56.20%
Shares Short Prior Month12.27M
Average Daily Volume Last 10 Day1.5M
Average Daily Volume In Three Month1.89M
Earnings Growth45.90%
Shares Percent Shares Out6.76%
Earnings Quarterly Growth43.80%
Gross Margins70.10%
Short Percent Of Float12.69%
Forward Price Earnings-19.17
Float Shares206.72M
Fifty Two Week High21.46
Enterprise Value To Ebitda7.37
Fifty Day Average11.08
Two Hundred Day Average10.05
Enterprise Value To Revenue4.32
Please continue to Trending Equities. Note that the Abcellera Biologics information on this page should be used as a complementary analysis to other Abcellera Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Abcellera Stock analysis

When running Abcellera Biologics price analysis, check to measure Abcellera Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera Biologics is operating at the current time. Most of Abcellera Biologics' value examination focuses on studying past and present price action to predict the probability of Abcellera Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abcellera Biologics' price. Additionally, you may evaluate how the addition of Abcellera Biologics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Abcellera Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abcellera Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.